Drugs / BL1332
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT06978244 | Jul 2025 → Nov 2026 expected | — | Bausch & Lomb Incorporated | Active not recruiting | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT07412496 | Apr 2026 → Feb 2027 expected | neuropathy, painful | Bausch & Lomb Incorporated | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-24 | Bausch Health Americas, Inc. | Results Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results bausch.com ↗
Positive Phase 1b Results Confirm TRPV1 Mechanism in Humans and Support Continued Development of BL1332; Phase 2 Results Expected Within Next Few Months |
| 2026-04-30 | Bausch Health Americas, Inc. | Results Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting bausch.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-24 | Bausch Health Americas, Inc. | Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results bausch.com ↗ |
| 2026-04-30 | Bausch Health Americas, Inc. | Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting bausch.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL1332 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07412496 ↗ |
| Route | Topical | “administered as topical ocular drops” NCT06978244 ↗ |